EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma

// Hsuan-Yu Chen 1, 2, 3 , Chia-Hsin Liu 1, 4, 5, * , Ya-Hsuan Chang 1, * , Sung-Liang Yu 6 , Bing-Ching Ho 6 , Chung-Ping Hsu 7 , Tsung-Ying Yang 7 , Kun-Chieh Chen 7 , Kuo-Hsuan Hsu 7 , Jeng-Sen Tseng 7 , Jiun-Yi Hsia 7 , Cheng-Yen Chuang 7 , Chi-Sheng Chang 6 , Yu-Cheng Li 1 , Ker-Chau Li 1 , Gee-Chen Chang 7, 8, 9 , Pan-Chyr Yang 6, 10, 11 1 Institute of Statistical Sciences, Academia Sinica, Taipei, Taiwan 2 College of Medicine, National Taiwan University, Taipei, Taiwan 3 College of Life Science, National Taiwan University, Taipei, Taiwan 4 Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica, Taipei, Taiwan 5 Institute of Biomedical Informatics, National Yang-Ming University, Taipei, Taiwan 6 Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan 7 Taichung Veterans General Hospital, Taichung, Taiwan 8 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan 9 Comprehensive Cancer Center, Taichung Veterans General Hospital, Taichung, Taiwan 10 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan 11 Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan * Chia-Hsin Liu and Ya-Hsuan Chang contributed equally as the first author Correspondence to: Hsuan-Yu Chen, e-mail: hychen@stat.sinica.edu.tw Gee-Chen Chang, e-mail: august@vghtc.gov.tw Keywords: lung adenocarcinoma, DNA copy number abundance, ErbB family, EGFR-activating mutation, prognosis Received: July 07, 2015 Accepted: January 12, 2016 Published: January 27, 2016 ABSTRACT In this study, EGFR -activating mutation status and DNA copy number abundances of members of ErbB family were measured in 261 lung adenocarcinomas. The associations between DNA copy number abundances of ErbB family, EGFR -activating mutation status, and prognosis were explored. Results showed that DNA copy number abundances of EGFR , ERBB2 , ERBB3 , and ERBB4 had associations with overall survival in lung adenocarcinoma with EGFR -activating mutations. In the stratification analysis, only ERBB2 showed significant discrepancy in patients carrying wild type EGFR and other members of ErbB family in patients carrying EGFR -activating mutation. This indicated that CNAs of ErbB family had effect modifications of EGFR -activating mutation status. Findings of this study demonstrate potential molecular guidance of patient management of lung adenocarcinoma with or without EGFR -activating mutations.